• Feature ArticlesFeature Articles

    China Regulatory Reform: An Update on Review Timelines and Drug Lag

    This article provides three case studies with an assessment of the impact of the regulatory changes and insight into the importance of including China in a global strategy for clinical development and drug registration. Introduction China has implemented a series of regulatory changes and improvements through a comprehensive regulatory reform starting in August 2015. The largely shortened new drug review timeline provides one of the biggest impacts for the pharmaceuti...